FY2026 EPS Forecast for Akebia Therapeutics Cut by Analyst

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Investment analysts at HC Wainwright lowered their FY2026 EPS estimates for Akebia Therapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will earn ($0.12) per share for the year, down from their previous forecast of ($0.08). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q4 2026 earnings at ($0.03) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.07) EPS, FY2029 earnings at $0.04 EPS and FY2030 earnings at $0.15 EPS.

Other analysts have also recently issued reports about the company. Zacks Research upgraded Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Leerink Partners cut Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 price objective for the company. in a report on Friday. Wall Street Zen downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akebia Therapeutics in a report on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Akebia Therapeutics presently has a consensus rating of “Hold” and an average price target of $3.75.

Akebia Therapeutics Price Performance

Akebia Therapeutics stock opened at $0.84 on Monday. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.43 and a quick ratio of 1.35. The company has a market capitalization of $233.88 million, a PE ratio of -7.67 and a beta of 0.26. Akebia Therapeutics has a one year low of $0.82 and a one year high of $3.44. The business has a 50 day simple moving average of $1.16 and a 200 day simple moving average of $1.26.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. Akebia Therapeutics had a negative return on equity of 88.88% and a negative net margin of 13.54%.The company had revenue of $49.13 million for the quarter, compared to the consensus estimate of $48.85 million.

Institutional Trading of Akebia Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Baird Financial Group Inc. lifted its position in Akebia Therapeutics by 23.0% during the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 4,000 shares in the last quarter. AQR Capital Management LLC grew its holdings in Akebia Therapeutics by 13.1% during the 1st quarter. AQR Capital Management LLC now owns 176,961 shares of the biopharmaceutical company’s stock worth $340,000 after acquiring an additional 20,499 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Akebia Therapeutics by 9.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 137,897 shares of the biopharmaceutical company’s stock valued at $265,000 after acquiring an additional 11,517 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Akebia Therapeutics by 171.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company’s stock valued at $5,231,000 after acquiring an additional 1,722,245 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Akebia Therapeutics by 123.0% in the second quarter. JPMorgan Chase & Co. now owns 1,652,746 shares of the biopharmaceutical company’s stock worth $6,016,000 after acquiring an additional 911,585 shares during the last quarter. 33.92% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Erik Ostrowski sold 56,019 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $1.11, for a total transaction of $62,181.09. Following the completion of the sale, the chief financial officer directly owned 616,616 shares of the company’s stock, valued at $684,443.76. This trade represents a 8.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.30% of the stock is owned by corporate insiders.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.